10 min read
Highlights
The "Trifecta of Scepticism" that shaped cultivated meat doubt is now colliding with a very different scientific and market reality.
- The Trifecta of Scepticism: Joe Fassler’s 2021 The Counter piece, David Humbird’s 2021 TEA, and the UC Davis carbon footprint study from Risner et al. (2023) became the three most-cited pillars of doubt.
- Environmental Reframe: The UC Davis emissions argument was built on pharmaceutical-grade purification assumptions that the industry is now moving beyond in favour of food-grade systems.
- Engineering Leapfrog: The 2024 Nature Food work from Pasitka et al. shows that metabolic waste and cell-density barriers are no longer the brick wall critics assumed.
- Market Reality Check: The 2025 Lever VC report validates that cost curves are moving sharply downward, especially in media and process design.
- Visionary Leadership: Boards must stop evaluating future disruptions based on current snapshots and start reading the trajectory.
In 2021, a long-form article in The Counter sent shockwaves through the food technology sector. Titled "Lab-grown meat is supposed to be inevitable. The science tells a different story," it featured a rigorous Techno-Economic Analysis (TEA) by chemical engineer David Humbird.
Humbird’s conclusion was blunt; cultivated meat would never be commercially viable. He argued that the sterility requirements, the cost of the "soup" (media), and the sheer physical limits of biology made the whole endeavour a pipe dream. For many in the traditional meat industry and even some corporate boards, this was the "I told you so" moment. And yes, very gently, I’ll say it; some of us could already see in 2021 that these critiques were far too static for a fast-moving technological and geopolitical future.
But here is the problem with Humbird’s analysis and the critics who still quote it —
You can't evaluate technologies that don't exist yet!
Before we go further, it’s worth acknowledging what I’d call the Trifecta of Skepticism. These are the three reports that have done the most to fuel cultivated meat doubt over the past few years.
- Joe Fassler’s 2021 piece in The Counter, which gave the sceptical narrative reach and cultural legitimacy.
- David Humbird’s 2021 TEA, which framed cultivated meat as structurally uneconomic at scale.
- The UC Davis carbon footprint study by Risner et al. (2023), which argued cultivated meat could have a worse climate profile than conventional beef under certain assumptions.
Taken together, these three works created a powerful storyline — too expensive, too complex, and potentially worse for the planet anyway. That’s the storyline many boards, investors, and incumbents locked onto. The problem? It was built on assumptions that were already ageing badly.
What I want to do here is contrast that scepticism with the scientific punch back that emerged in 2024 and 2025. Because this is where the conversation changes. Not with hype. With updated engineering, better process science, and actual market evidence.
When we look at the world through my TECHXponential™ lens, we see that technology doesn't move in a straight line. It moves exponentially. What was "scientifically impossible" in 2021 is becoming "commercially viable" in 2026. Let's look at why the critics were mostly wrong and what this means for the future of food.
1. The Media Cost Revolution: From Pharma to Food
One of the loudest arguments in the 2021 critique was the cost of the culture medium; the nutrient-rich liquid the cells eat. Humbird estimated that even under optimistic scenarios, the cost of growth factors (the proteins that tell cells to multiply) would remain prohibitively expensive because they required pharmaceutical-grade manufacturing.
This same assumption also sat underneath the later environmental critique from UC Davis. The Risner et al. (2023) carbon footprint study became one of the most widely quoted attacks on cultivated meat because it suggested the product could be dramatically more emissions-intensive than conventional beef. But here’s the catch; that conclusion depended heavily on the use of pharma-grade purification standards for inputs. In other words, it modelled an industry as if it were producing injectable therapeutics rather than food.
That distinction matters enormously. The cultivated meat sector has been moving away from those pharmaceutical assumptions and towards food-grade purification, where the processing burden, energy intensity, and cost structure are fundamentally different. So, if your emissions model assumes a purification standard the industry no longer needs, then your carbon conclusion starts to wobble. A lot.
Fast forward to the 2024 Nature Food work and then the 2025 market analysis from Lever VC. The story is no longer about whether pharma economics can somehow be squeezed into food. It’s about the fact that the sector is redesigning the production stack for food from the ground up. Researchers and companies have successfully developed animal-component-free media priced at just USD 0.63 per litre.
How did they do it? They didn't just try to make pharma-grade media cheaper; they invented a new way to brew it. By using precision fermentation, essentially using microbes as tiny factories, they are now "brewing" growth factors like beer. We’ve moved from relying on expensive bovine serum to high-yield, microbial-produced nutrients. When you drop the cost of your primary input by 99%, the economic "impossibility" starts to look like a massive opportunity.
And now we can add another very specific proof point. Deco Labs, a Tufts University spinout, has announced its cAlbumin breakthrough; a plant-based albumin replacement created by upcycling rapeseed meal from canola oil production. That matters because it takes what was once treated as a costly, pharmaceutical-style serum replacement problem and reframes it as a circular food-system input problem. In plain English, the industry is starting to feed cells with the byproducts of agriculture rather than the ultra-refined ingredients of biopharma.
Even better, Deco Labs projects that cAlbumin could contribute as little as USD 0.02 per litre of cell culture media at scale. That is a huge scientific punch back against the 2021 claim that growth factors and serum replacements would always remain the primary cost barrier. I believe this is exactly the kind of shift the sceptics missed — the transition from expensive pharmaceutical inputs to low-cost, upcycled food-system inputs.
This is the first part of the scientific punch back; if the purification regime changes from pharma-grade to food-grade, both the cost case and the climate case change with it.
2. The Sterility Myth: Moving from Cleanrooms to Automated Aseptic
The 2021 critique argued that because animal cells have no immune system, a single rogue bacterium in a massive tank would ruin the entire batch. Humbird claimed this would require "Class 100" cleanrooms, the kind used to make microchips or vaccines, making the facility costs astronomically high.
However, the industry has pivoted away from the "giant cleanroom" model. Companies like Meatly have demonstrated a shift toward Automated Aseptic Systems. Instead of trying to keep an entire building sterile, they use modular, self-contained, and highly automated bioreactors.
By 2025, Meatly had developed 320L reactors costing roughly USD 16,000 (approx. £12,500); a 95% reduction in hardware costs compared to traditional pharma vessels. They aren't building vaccine plants; they are building highly automated food factories. It’s a subtle but vital distinction that the early critics missed.
3. Solving the Metabolic Wall: The Perfusion Solution
A major technical hurdle cited in the past was "metabolic waste." Just like humans, cells produce waste (ammonia and lactate) as they grow. In a traditional batch process, the cells eventually drown in their own "poop," limiting how many cells you can grow in a single tank.
This is where the 2024 paper by Pasitka et al. in Nature Food becomes so important. One of the most persistent arguments from the sceptics was that the biology itself wouldn’t cooperate. Cells wouldn’t reach the densities required. Waste would accumulate too quickly. The process would stall before the economics ever worked. That argument sounded solid in 2021. It sounds a lot less solid now.
The solution? Continuous Perfusion and Tangential Flow Filtration (TFF).
Think of this as a dialysis machine for meat production. Instead of letting the waste build up, the liquid is constantly cycled through a filter that removes waste and replenishes nutrients while keeping the cells safely inside the reactor.
This isn't just theory anymore. The 2024 Nature Food analysis by Pasitka et al. showed that this continuous manufacturing process allows for cell densities that were previously thought to be biologically impossible. We are seeing densities of 130 million cells per mL. This productivity boost changes the entire capital expenditure (CAPEX) equation.
More importantly, it means two of the biggest technical criticisms — metabolic waste accumulation and insufficient cell density — have been leapfrogged by process engineering. Not talked around. Leapfrogged. That’s the second part of the scientific punch back.
4. The Scale Shift: Why 20,000L Beats 200,000L
Humbird’s 2021 model assumed that to reach cost parity, we would need 200,000-litre "mega-tanks." He then correctly pointed out that tanks of that size are engineering nightmares due to hydrostatic pressure and oxygen transfer issues.
What he didn't foresee was that we wouldn't need 200,000L tanks. Because of the high-density perfusion tech mentioned above, a 20,000L tank today can produce as much meat as a 100,000L tank could in the 2021 models.
By scaling "out" with modular, high-density units rather than just scaling "up" into massive vessels, the industry has bypassed the physical limits Humbird described. This modular approach is much more attractive to investors and boards because it allows for incremental expansion rather than requiring a billion-dollar "bet-the-company" facility from day one.
And this is where the Lever VC 2025 report matters. It acts as the market reality check. Not a lab fantasy. Not a speculative pitch deck. A commercial read on where the cost curve is actually going. The report validates what many of us have been saying for a while; cost decline is real, media economics are improving, and process innovations are turning yesterday’s impossible assumptions into today’s outdated models.
So when critics still point back to 2021 as if nothing has changed, my response is simple; the market has moved, the science has moved, and the hardware has moved. You can read more about how these shifts are impacting the future of protein on my blog.
5. Nutritional Equivalence: A Molecular Breakthrough
There’s one more criticism from the 2021 era that deserves a direct response; the idea that cultivated meat might one day look like meat, but never truly match the nutritional profile of conventional meat. That argument is now looking increasingly shaky.
A June 2026 study published on ScienceDirect (PII: S0963996926013104) delivers what I’d call the final scientific punch back. This empirical research compared cultivated biomass protein with conventional pork and found something critically important; we are not just engineering resemblance. We are engineering nutritional parity at the molecular level.
Here are the key takeaways.
- Nutritional Parity. The study found that cultivated biomass protein matched conventional pork in overall protein and fat levels.
- Amino Acid Profile. The essential amino acid profile and protein quality indices were a direct match to pork, which matters because protein isn’t just about quantity. It’s about composition and biological usefulness.
- Superior Bioavailability. The research showed potentially higher bioaccessibility for essential minerals like Iron (Fe) and Zinc (Zn) compared with conventional meat.
- Digestibility. Using the INFOGEST model (a standardised in vitro digestion method), the study showed cultivated meat was just as digestible as conventional pork.
That changes the conversation in a big way. For years, doubters have implied that cultivated meat would be some nutritionally compromised imitation; something visually convincing but biologically second-rate. This new evidence points in the opposite direction. I believe it shows that cultivated meat can be nutritionally identical, and in some respects potentially superior, to conventional meat.
This matters far beyond one paper. It tells regulators, investors, food companies, and consumers that the future product is not merely a copy of meat’s appearance. It is increasingly matching meat’s functional nutritional value; right down to amino acids, digestibility, and mineral accessibility. That’s not cosmetic innovation. That’s systems-level food science.
6. The TECHXponential™ Reality: 11 Billion Entities by 2050
Why does this matter so much? Because by 2050, we will have 9.7 billion humans on this planet. But that’s only half the story. When we factor in our 1.3 billion pet cats and dogs, we are actually looking at 11 billion entities that need to be fed high-quality protein.
Current industrial animal agriculture simply cannot scale to meet that demand without destroying the planetary systems we rely on. We don't have a choice; we must make cultivated meat work.
I believe that the "impossible" labels of 2021 will be remembered in the same way we remember the "experts" who said aeroplanes would never carry more than two people or that the internet was just a passing fad for academics.
The Sovereignty Factor: Beyond the Spreadsheet
There’s another flaw in the 2021 critique that matters even more in 2026; it treated "viability" as if it were a universal spreadsheet exercise rather than a national strategic calculation.
Critics like Humbird focused on cost curves, engineering constraints, and facility economics. Fair enough. But they failed to account for food sovereignty, a nation’s ability to control the means of producing critical nutrition within its own borders. That omission is no longer a minor oversight. It is now central to the debate.
This is exactly the point I began making in my May 2025 NZ Food Technology News opinion piece, "It’s only impossible… until it’s not", where I challenged the static nature of these critiques. My argument then was simple; if you assess an exponential technology using fixed assumptions, you will almost always arrive at the wrong answer. What I want to add now is that if you assess a food technology without including geopolitics, energy security, and sovereign resilience, your model is even weaker.
Look at the recent supply chain disruptions and the ongoing tensions in the Strait of Hormuz. If a nation faces a blockade or severe disruption to fertiliser imports or LNG supplies, both essential to ammonia production and, by extension, modern food production, then the definition of "commercially viable" changes very quickly. In that scenario, a local cultivated meat facility is not some futuristic luxury. It becomes a strategic national asset.
That’s why I believe the world is finally waking up to something I’ve been saying for a while, that we must distribute the means of production, not just the outputs. Shipping finished calories around the world is one model. Building distributed, resilient food manufacturing capacity closer to where people live is the next one. A gentle "I told you so"? Absolutely. Because this is where the conversation was always heading.
If you’ve been following my broader work, this connects directly to my earlier discussions on the Strait of Hormuz and the fragility of global food systems. The logic is straightforward now; food security is national security. And once you accept that, the old 2021 critiques start to look incomplete, not because they were foolish, but because they were analysing a future industry without accounting for a future world.
The Leadership Trap: Don't Manage by Snapshot
The biggest risk for C-suite executives and Boards of Directors today is the "Snapshot Trap." If you look at a snapshot of cultivated meat in 2021, Humbird was right. But if you look at the trajectory of the technology, the exponential drop in media costs, the rise of continuous manufacturing, and the modularisation of hardware, the picture is entirely different.
In my TECHXponential™ framework, we understand that.
New Assumptions + New Hardware + Exponential Scaling = A New Industry Reality.
The critics of 2021 were looking at the tools of the past to judge the possibilities of the future. Don't make the same mistake. The question for your organisation isn't "if" this technology will arrive, but how you will lead when it does.
References:
- Fassler, J. (2021). "Lab-grown meat is supposed to be inevitable. The science tells a different story." The Counter.
- Humbird, D. (2021). "Scale-up economics for cultured meat." Biotechnology and Bioengineering.
- Risner, D., et al. (2023). "Environmental impacts of cultivated meat: a cradle-to-gate life cycle assessment." UC Davis / preprint analysis.
- Pasitka, A., et al. (2024). "Empirical economic analysis shows cost-effective continuous manufacturing of cultivated meat." Nature Food.
- Lever VC. (2025). Cultivated meat sector market analysis report.
- Deco Labs. (2026). cAlbumin plant-based albumin replacement announcement and scale-cost projections.
- ScienceDirect. (2026). "Analysis of nutritional properties and in vitro digestibility characteristics of cultivated biomass protein." PII: S0963996926013104.
- Meatly (2025). "Modular Aseptic Scalability Report." Industry White Paper.
To continue the conversation email me at tony@tonyhunterspeaker.com